The latest price target for Akero Therapeutics (NASDAQ:AKRO) was reported by UBS on January 31, 2025. The analyst firm set a price target for $109.00 expecting AKRO to rise to within 12 months (a possible 101.70% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Akero Therapeutics (NASDAQ:AKRO) was provided by UBS, and Akero Therapeutics maintained their buy rating.

The last upgrade for Akero Therapeutics Inc happened on January 30, 2025 when B of A Securities raised their price target to $63. B of A Securities previously had a neutral for Akero Therapeutics Inc.

There is no last downgrade for Akero Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akero Therapeutics was filed on January 31, 2025 so you should expect the next rating to be made available sometime around January 31, 2026.

While ratings are subjective and will change, the latest Akero Therapeutics (AKRO) rating was a maintained with a price target of $42.00 to $109.00. The current price Akero Therapeutics (AKRO) is trading at is $54.04, which is within the analyst’s predicted range.